Learn more

SUN PHARMA ADVANCED RES CO LTD

Overview
  • Total Patents
    264
  • GoodIP Patent Rank
    16,637
  • Filing trend
    ⇩ 25.0%
About

SUN PHARMA ADVANCED RES CO LTD has a total of 264 patent applications. It decreased the IP activity by 25.0%. Its first patent ever was published in 2002. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and United States. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and medical technology are RECORDATI IND CHIMICA E FARMACEUTICA S P A, ADIPHARM EAD and OOO KONSORTSIUM PIK.

Patent filings per year

Chart showing SUN PHARMA ADVANCED RES CO LTDs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Bhowmick Subhas Balaram 79
#2 Khopade Ajay Jaysingh 60
#3 Thennati Rajamannar 53
#4 Halder Arindam 39
#5 Chitturi Trinadha Rao 34
#6 Dharmadhikari Nitin Bhalachandra 33
#7 Kane Prashant 29
#8 Patel Gopalkumar Chimanlal 28
#9 Patel Jiten Ranchhodbhai 28
#10 Sheth Gaurav Sanjivkumar 28

Latest patents

Publication Filing date Title
US2021115038A1 Malic enzyme inhibitors
WO2021005583A1 Camptothecin derivatives with a disulfide moiety and a piperazine moiety
WO2020250133A1 Treatment for synucleinopathies
WO2017168435A1 Viscoelastic gel of liraglutide adapted for once-weekly or once bi-weekly administration
WO2017056115A1 Novel n-aryl containing fused heterocyclic compounds
EP3150196A1 Process for the preparation of unilamellar liposomal composition
WO2017037742A1 Oral pharmaceutical composition of tizandine
WO2017025990A1 Long acting liraglutide compositions
AU2016293508A1 Multiple pill abuse-resistant immediate release solid dosage form of hydrocodone
US2018140549A1 Method of treating carcinoma
EP3261619A1 Nanoparticulate composition
EP3261618A1 Method of preparing nanoparticulate topical composition
US2017056401A1 Stable multiparticulate pharmaceutical composition of rosuvastatin
WO2016120892A1 Abuse deterrent controlled release solid dosage form
WO2016016908A1 Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
WO2016013031A1 Liposome composition and method of preparing the liposome
US2015290277A1 Pharmaceutical composition
WO2015145461A1 Abuse deterrent immediate release biphasic matrix solid dosage form
WO2015075744A1 Novel intermediate of tapentadol
SG11201509680TA Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.